Twist Bioscience (NASDAQ:TWST) Trading Up 10.3% - Time to Buy?

Shares of Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) rose 10.3% during mid-day trading on Tuesday . The company traded as high as $39.70 and last traded at $40.48. Approximately 1,102,103 shares were traded during mid-day trading, an increase of 12% from the average daily volume of 986,587 shares. The stock had previously closed at $36.71.

Wall Street Analyst Weigh In

TWST has been the topic of several analyst reports. Robert W. Baird raised their target price on Twist Bioscience from $48.00 to $54.00 and gave the company an "outperform" rating in a research report on Tuesday, February 4th. TD Cowen restated a "buy" rating and set a $58.00 price objective on shares of Twist Bioscience in a research note on Tuesday, November 26th. Scotiabank reiterated an "outperform" rating on shares of Twist Bioscience in a research report on Tuesday, February 4th. Barclays set a $58.00 price target on shares of Twist Bioscience and gave the stock an "overweight" rating in a research report on Monday, February 3rd. Finally, Wolfe Research began coverage on shares of Twist Bioscience in a report on Friday, December 13th. They issued an "outperform" rating and a $60.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, Twist Bioscience currently has an average rating of "Moderate Buy" and a consensus target price of $54.40.

Twist Bioscience Price Performance

The company has a debt-to-equity ratio of 0.03, a current ratio of 4.96 and a quick ratio of 4.62. The firm has a market cap of $2.33 billion, a price-to-earnings ratio of -11.58 and a beta of 2.15. The stock's fifty day moving average price is $46.33 and its 200-day moving average price is $45.43.

Remove Ads

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.62) by $0.09. The company had revenue of $88.70 million during the quarter, compared to the consensus estimate of $86.96 million. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The company's revenue was up 24.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.75) EPS. Equities research analysts predict that Twist Bioscience Co. will post -2.12 EPS for the current fiscal year.

Insider Activity

In related news, CEO Emily M. Leproust sold 2,402 shares of the stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $40.91, for a total transaction of $98,265.82. Following the completion of the sale, the chief executive officer now owns 662,692 shares in the company, valued at $27,110,729.72. This represents a 0.36 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Paula Green sold 918 shares of Twist Bioscience stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $40.91, for a total value of $37,555.38. Following the completion of the transaction, the senior vice president now directly owns 130,912 shares in the company, valued at approximately $5,355,609.92. This represents a 0.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 33,845 shares of company stock valued at $1,603,945. Insiders own 3.01% of the company's stock.

Hedge Funds Weigh In On Twist Bioscience

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Wilmington Savings Fund Society FSB bought a new stake in shares of Twist Bioscience in the 3rd quarter worth about $34,000. Van ECK Associates Corp grew its stake in shares of Twist Bioscience by 56.4% during the fourth quarter. Van ECK Associates Corp now owns 740 shares of the company's stock valued at $34,000 after purchasing an additional 267 shares during the last quarter. Banque Transatlantique SA acquired a new stake in shares of Twist Bioscience in the fourth quarter valued at approximately $43,000. GF Fund Management CO. LTD. bought a new position in Twist Bioscience in the 4th quarter worth approximately $58,000. Finally, US Bancorp DE lifted its holdings in Twist Bioscience by 72.0% during the 4th quarter. US Bancorp DE now owns 1,436 shares of the company's stock worth $67,000 after buying an additional 601 shares in the last quarter.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.